About Inizio

Inizio partners with health and life sciences companies across the full commercialization journey, from early-stage clinical development through to loss of exclusivity. With more than 10,500 experts across 50 countries, the company combines industry knowledge with data-driven insights, advanced technology, and AI to simplify complex challenges and accelerate decision-making at every pivotal moment. Formed in 2022 through the merger of Ashfield and Huntsworth, Inizio operates through five specialized business units. The company supported over 60% of top pharmaceutical product launches in recent years, delivering tailored solutions that maximize asset value, unlock market access, and help more patients access treatments faster.